Patent ID: 8318425
Filing Date: 2012-11-27
Classification: A61K,A61P,C07K,C12N,G01N

Abstract:
1. A method of treating HIV-1 infection in a patient, comprising: determining whether the HIV-1 contains a mutation or a substitution of Ala to Val at a position corresponding to residue 364 or 366 of HIV-1 Gag (residue 1 of SP1) as compared to the sequence of either the wild type strain NL4-3 or the wild type strain RF; and administering to a patient in need thereof a compound that inhibits p25 (CA-SP1) processing to p24 (CA) if the HIV-1 does not contain the mutation, wherein said compound is selected form the group consisting of (a) 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (DSB), (b) 3-0-(3′,3′-dimethylsuccinyl) betulin, (c) 3-O-(3′,3′-dimethylglutaryl) betulin, (d) 3-O-(3′,3′-dimethylsuccinyl) dihydrobetulinic acid, (e) 3-O-(3′,3′-dimethylglutaryl) betulinic acid, (f) (3′,3′-dimethylglutaryl) dihydrobetulinic acid, (g) 3-O-diglycolyl-betulinic acid, (h) 3-O-diglycolyl-dihydrobetulinic acid, (i) a pharmaceutically acceptable salt of any of (a)-(h), and (j) combinations thereof.